Cullinan Therapeutics (CGEM) Treasury Shares (2020 - 2025)

Cullinan Therapeutics' Treasury Shares history runs 5 years deep, the most recent figure standing at $1.6 million for Q4 2025.

• On a quarterly basis, Treasury Shares rose 26.83% year-over-year to $1.6 million in Q4 2025; TTM through Dec 2025 was $1.6 million, a 26.83% increase from a year earlier, with the FY2025 full-year figure at $85.6 million, up 6499.85% from the prior year.
• Treasury Shares eased to $1.6 million in Q4 2025 per CGEM's latest filing, from $85.6 million in the prior quarter.
• Across five years, Treasury Shares topped out at $85.6 million in Q2 2023 and bottomed at $15.0 in Q4 2022.
• The 4-year median for Treasury Shares is $85.6 million (2023), against an average of $57.4 million.
• Across the five-year window, Treasury Shares soared 5359900.0% in 2023 and changed 0.0% in 2024, its largest moves.
• Year by year, Treasury Shares stood at $15.0 in 2022, then surged by 5359900.0% to $804000.0 in 2023, then surged by 61.32% to $1.3 million in 2024, then grew by 26.83% to $1.6 million in 2025.
• Per Business Quant, the three latest CGEM Treasury Shares figures stand at $1.6 million (Q4 2025), $85.6 million (Q3 2025), and $85.6 million (Q2 2025).